TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Symbio Pharmaceuticals Limited ( (JP:4582) ) just unveiled an update.
SymBio Pharmaceuticals Limited has revised its earnings forecast for the fiscal year ending December 31, 2025, reflecting a decrease in expected net sales due to a shift towards generic drugs and expanded treatment options impacting its product TREAKISYM®. The company anticipates a net sales reduction of 24.7% compared to previous forecasts, alongside a slight decrease in operating loss. Despite these challenges, SymBio is progressing with its clinical trials, which could impact its future market positioning.
More about Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited is a pharmaceutical company based in Tokyo, Japan. It focuses on the development and commercialization of drugs, with a particular emphasis on treatments for cancer and rare diseases. The company is engaged in clinical trials for various conditions, including adenovirus infection after hematopoietic stem cell transplantation and NK/T-cell lymphoma.
Average Trading Volume: 455,347
Technical Sentiment Signal: Sell
Current Market Cap: Yen8.14B
For a thorough assessment of 4582 stock, go to TipRanks’ Stock Analysis page.